Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 8 | 2023 | 1502 | 0.840 |
Why?
|
| Animals, Domestic | 2 | 2021 | 8 | 0.820 |
Why?
|
| Macrophages | 4 | 2013 | 439 | 0.790 |
Why?
|
| Lactase | 1 | 2021 | 1 | 0.790 |
Why?
|
| Lymphotoxin-alpha | 1 | 2019 | 4 | 0.720 |
Why?
|
| Major Histocompatibility Complex | 1 | 2019 | 21 | 0.710 |
Why?
|
| Selection, Genetic | 3 | 2018 | 54 | 0.680 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 268 | 0.650 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 191 | 0.620 |
Why?
|
| Demography | 2 | 2021 | 175 | 0.600 |
Why?
|
| Interferon-gamma | 1 | 2018 | 250 | 0.580 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2013 | 43 | 0.560 |
Why?
|
| Africa | 3 | 2021 | 76 | 0.530 |
Why?
|
| Renal Replacement Therapy | 1 | 2012 | 8 | 0.430 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 16 | 0.430 |
Why?
|
| Mortality | 1 | 2012 | 145 | 0.390 |
Why?
|
| Registries | 1 | 2012 | 335 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 233 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 767 | 0.350 |
Why?
|
| Hospitalization | 1 | 2012 | 388 | 0.340 |
Why?
|
| Gene Frequency | 2 | 2019 | 195 | 0.320 |
Why?
|
| Prognosis | 6 | 2023 | 739 | 0.320 |
Why?
|
| Genetic Variation | 4 | 2017 | 387 | 0.300 |
Why?
|
| MicroRNAs | 2 | 2023 | 426 | 0.290 |
Why?
|
| Humans | 22 | 2023 | 37093 | 0.270 |
Why?
|
| Genetics, Population | 2 | 2019 | 100 | 0.260 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2022 | 17 | 0.220 |
Why?
|
| Radiology | 1 | 2022 | 10 | 0.220 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 275 | 0.220 |
Why?
|
| Gastrointestinal Diseases | 1 | 2022 | 42 | 0.210 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 77 | 0.190 |
Why?
|
| Female | 13 | 2023 | 20969 | 0.190 |
Why?
|
| Human Genome Project | 1 | 2019 | 7 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2019 | 18 | 0.180 |
Why?
|
| Hominidae | 1 | 2019 | 11 | 0.180 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 85 | 0.180 |
Why?
|
| Cattle | 1 | 2021 | 477 | 0.170 |
Why?
|
| Haplotypes | 1 | 2019 | 182 | 0.170 |
Why?
|
| Animals | 8 | 2021 | 15081 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 474 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 47 | 0.130 |
Why?
|
| Aged | 5 | 2021 | 6741 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 37 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 807 | 0.130 |
Why?
|
| Databases, Protein | 2 | 2006 | 48 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2016 | 587 | 0.130 |
Why?
|
| Middle Aged | 6 | 2021 | 10129 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 2013 | 30 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 113 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2013 | 38 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2013 | 33 | 0.110 |
Why?
|
| Anilides | 1 | 2013 | 28 | 0.110 |
Why?
|
| Trypanosomiasis, African | 1 | 2013 | 23 | 0.110 |
Why?
|
| Columbidae | 1 | 2013 | 47 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 26 | 0.110 |
Why?
|
| Head | 1 | 2013 | 27 | 0.110 |
Why?
|
| Trypanocidal Agents | 1 | 2013 | 39 | 0.110 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2012 | 4 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 75 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 19 | 0.110 |
Why?
|
| Patient Admission | 1 | 2012 | 41 | 0.110 |
Why?
|
| Proteins | 2 | 2006 | 369 | 0.100 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2013 | 83 | 0.100 |
Why?
|
| Adult | 5 | 2021 | 11712 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 194 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 29 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2012 | 210 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2012 | 187 | 0.100 |
Why?
|
| Rosaceae | 1 | 2010 | 1 | 0.090 |
Why?
|
| Prunus | 1 | 2010 | 2 | 0.090 |
Why?
|
| Social Class | 1 | 2012 | 247 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 128 | 0.090 |
Why?
|
| Recurrence | 1 | 2010 | 131 | 0.090 |
Why?
|
| Comorbidity | 1 | 2012 | 623 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2010 | 325 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1067 | 0.080 |
Why?
|
| Computational Biology | 3 | 2021 | 293 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2026 | 0.080 |
Why?
|
| Algorithms | 2 | 2017 | 465 | 0.080 |
Why?
|
| Software | 2 | 2006 | 217 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 400 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2017 | 195 | 0.070 |
Why?
|
| Sequence Analysis, Protein | 1 | 2006 | 50 | 0.070 |
Why?
|
| Genomics | 2 | 2023 | 223 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 626 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2017 | 172 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1198 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 59 | 0.060 |
Why?
|
| Consensus | 1 | 2022 | 45 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 132 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 21 | 0.050 |
Why?
|
| Receptor, erbB-2 | 1 | 2023 | 133 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 24 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4268 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 82 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 182 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 1033 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 107 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 214 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 441 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 138 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1207 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 237 | 0.050 |
Why?
|
| RNA Interference | 1 | 2021 | 243 | 0.050 |
Why?
|
| Male | 3 | 2016 | 20025 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 481 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2017 | 77 | 0.040 |
Why?
|
| Exons | 1 | 2017 | 88 | 0.040 |
Why?
|
| Immune System | 1 | 2016 | 41 | 0.040 |
Why?
|
| New South Wales | 1 | 2016 | 1 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 64 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1180 | 0.030 |
Why?
|
| North America | 1 | 2016 | 67 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 333 | 0.030 |
Why?
|
| Markov Chains | 2 | 2006 | 35 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2013 | 3 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.030 |
Why?
|
| Myoblasts, Skeletal | 1 | 2013 | 7 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 225 | 0.030 |
Why?
|
| Feathers | 1 | 2013 | 3 | 0.030 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Breeding | 1 | 2013 | 21 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2013 | 89 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 96 | 0.030 |
Why?
|
| Mice | 3 | 2013 | 5913 | 0.030 |
Why?
|
| Animals, Wild | 1 | 2013 | 18 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 753 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 245 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 935 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 3483 | 0.030 |
Why?
|
| Genome | 1 | 2013 | 125 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 583 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 409 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 1369 | 0.030 |
Why?
|
| Cell Count | 1 | 2011 | 135 | 0.020 |
Why?
|
| Belgium | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA, Chloroplast | 1 | 2010 | 3 | 0.020 |
Why?
|
| Netherlands | 1 | 2010 | 10 | 0.020 |
Why?
|
| Climate | 1 | 2010 | 14 | 0.020 |
Why?
|
| DNA, Plant | 1 | 2010 | 13 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 24 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 898 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2010 | 59 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 101 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 96 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 251 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1568 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 644 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 219 | 0.020 |
Why?
|
| Ecosystem | 1 | 2010 | 123 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3562 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 571 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 602 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2006 | 17 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 494 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2006 | 62 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 111 | 0.020 |
Why?
|
| Internet | 1 | 2006 | 211 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 180 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2003 | 19 | 0.010 |
Why?
|
| Peptide Library | 1 | 2003 | 25 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 34 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2003 | 83 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 265 | 0.010 |
Why?
|
| United States | 1 | 2011 | 4223 | 0.010 |
Why?
|